Protease-Activated Receptor Signaling in Hemostasis and Inflammation

Protease-activated receptors (PARs) are a unique subfamily of G protein-coupled receptors that mediate the interface between coagulation and inflammatory cascades. Four family members (PAR1–PAR4) are activated by protease-mediated cleavage of their extracellular N-terminus, unveiling a tethered ligand that triggers signalling via G proteins and β-arrestin pathways. In the vasculature, PAR1 and PAR4 serve as principal thrombin receptors on platelets and endothelial cells, orchestrating platelet aggregation, endothelial barrier regulation and anticoagulant protein C activation, thereby governing haemostasis and thrombosis. Parallel PAR2 signalling by trypsin-like proteases contributes to endothelial inflammation, leukocyte recruitment and tissue regeneration, while crosstalk among PARs, ion channels and toll-like receptors fine-tunes the balance between repair and injury. Biased signalling through selective protease cleavage further diversifies PAR functions, enabling context-dependent modulation of coagulation and immune responses. Dysregulated PAR activity underlies pathological thrombosis, inflammatory bowel disease and autoimmune disorders, positioning PARs and their modulators as strategic therapeutic targets to restore vascular integrity and resolve inflammation.

Research from Nature Portfolio

A phase 2 clinical trial of a novel protein C activator administered during haemodialysis in end-stage renal disease patients demonstrated safety and tolerability without treatment-related bleeding or impaired vascular access haemostasis. The study supports targeted activation of the protein C pathway as a feasible antithrombotic and anti-inflammatory strategy in high-risk populations.

Protease-Activated Receptor Signaling in Hemostasis and Inflammation publication trend

The graph below shows the total number of articles in protease-activated receptor signaling in hemostasis and inflammation across all publications each year (not limited to Nature Index journals).

Technical terms

Protease-Activated Receptor (PAR): A G protein-coupled receptor activated by specific proteolytic cleavage that exposes an intramolecular tethered ligand to trigger intracellular signalling.

Haemostasis: The physiological process that stops bleeding through coordinated vascular constriction, platelet aggregation and coagulation cascade activation.

Tethered Ligand: The receptor-derived peptide generated by proteolytic cleavage that binds intramolecularly to activate PARs.

Biased Signalling: The ability of different proteases or cleavage sites to preferentially induce distinct intracellular pathways via the same receptor.

Platelet–Neutrophil Interaction: Cellular crosstalk between platelets and neutrophils that amplifies thrombo-inflammatory responses.

References

1. Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis Journal (2019).
2. Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Communication and Signaling (2013).
3. Biased Signaling of Protease-Activated Receptors. Frontiers in Endocrinology (2014).
4. Par2-mediated responses in inflammation and regeneration: choosing between repair and damage. Inflammation and Regeneration (2024).
5. Safety and tolerability of the protein C activator AB002 in end-stage renal disease patients on hemodialysis: a randomized phase 2 trial. Communications Medicine (2024).
6. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. Journal of Clinical Investigation (2023).
7. Controlling autoimmune diabetes onset by targeting Protease-Activated Receptor 2. Biomedicine & Pharmacotherapy (2024).
8. Chymotrypsin activity signals to intestinal epithelium by protease‐activated receptor‐dependent mechanisms. British Journal of Pharmacology (2024).